MedTrace Logo

Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia

NCT01078974 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-07-25

Study results available
· View outcomes & findings →

Summary

Pomalidomide is a newly discovered drug that may stop cancer cells from growing abnormally. Pomalidomide may also stimulate the immune system to fight the cancer cells and possibly improve the effectiveness of dexamethasone and rituximab to fight the Waldenstrom's Macroglobulinemia (WM) cancer cells. This drug have been used in multiple myeloma and information from these other research studies suggests that Pomalidomide may help to reduce or prevent the growth of cancer cells.

Conditions

  • Waldenstrom's Macroglobulinemia

Interventions

DRUG

pomalidomide

Taken orally once a day

DRUG

dexamethasone

Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

DRUG

rituximab

Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Steven P. Treon, MD, PhD

    lead OTHER

Principal Investigators

  • Steven P. Treon, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2015-09-30
Completion
2016-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01078974 on ClinicalTrials.gov